Figure 3 represents the cumulative risk of developing composite outcome and mortality in COVID-19 patients treated with Nirmatrelvir, whose peripheral blood CD4+ T cell and CD8+ T cell counts decreased significantly at admission. This evidence concerns the gene CD4 and COVID-19.